HESTERBIO

Hester Biosciences Share Price

 

 

Invest in Hester Biosciences with 1X leverage

Invest with MTF

Performance

  • Low
  • ₹1,563
  • High
  • ₹1,606
  • 52 Week Low
  • ₹1,243
  • 52 Week High
  • ₹2,497
  • Open Price₹1,596
  • Previous Close₹1,593
  • Volume1,219

Investment Returns

  • Over 1 Month -3.61%
  • Over 3 Month -19.14%
  • Over 6 Month -12.25%
  • Over 1 Year -34.12%

Smart Investing Starts Here Start SIP with Hester Biosciences for Steady Growth!

Invest Now

Hester Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30.7
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 1,347
  • P/B Ratio
  • 4
  • Average True Range
  • 38.81
  • EPS
  • 51.54
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -23.5
  • RSI
  • 38.54
  • MFI
  • 46.58

Hester Biosciences Financials

Hester Biosciences Technicals

EMA & SMA

Current Price
₹1,583.70
-9.3 (-0.58%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,609.23
  • 50 Day
  • ₹1,666.44
  • 100 Day
  • ₹1,737.92
  • 200 Day
  • ₹1,816.37

Resistance and Support

1584.43 Pivot Speed
  • R3 1,648.57
  • R2 1,627.43
  • R1 1,605.57
  • S1 1,562.57
  • S2 1,541.43
  • S3 1,519.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Hester Biosciences Ltd. is a leading manufacturer of animal healthcare products, specializing in vaccines and veterinary pharmaceuticals. With production facilities in India and Nepal, it serves domestic and international markets, focusing on livestock and poultry healthcare solutions.

Hester Biosciences has an operating revenue of Rs. 300.22 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 42%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 78 which is a FAIR score but needs to improve its earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Hester Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-01 Quarterly Results
2025-05-09 Audited Results & Final Dividend
2025-01-30 Quarterly Results
2024-10-28 Quarterly Results
Date Purpose Remarks
2025-08-06 FINAL Rs.7.00 per share(70%)Final Dividend
View Hester Biosciences Dividend History Arrow

Hester Biosciences F&O

Hester Biosciences Shareholding Pattern

53.73%
0%
0.53%
32.92%
12.82%

About Hester Biosciences

  • NSE Symbol
  • HESTERBIO
  • BSE Symbol
  • 524669
  • Managing Director & CEO
  • Mr. Rajiv Gandhi
  • ISIN
  • INE782E01017

Similar Stocks to Hester Biosciences

Hester Biosciences FAQs

Hester Biosciences share price is ₹1,583 As on 26 December, 2025 | 01:20

The Market Cap of Hester Biosciences is ₹1347.2 Cr As on 26 December, 2025 | 01:20

The P/E ratio of Hester Biosciences is 30.7 As on 26 December, 2025 | 01:20

The PB ratio of Hester Biosciences is 4 As on 26 December, 2025 | 01:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23